This design embodies the concept of “treating the same disease with different treatments.” For instance, in NSCLC, patients may be screened for EGFR mutations, ALK or ROS1 fusions, or KRAS and BRAF mutations and then assigned to the appropriate targeted inhibitor [116]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.